Investors' belief in the company's poor revenue performance is likely causing its low P/S ratio. The company's bleak revenue outlook is contributing to its low P/S. These conditions form a barrier for the share price at these levels.
Shanghai Henlius Biotech's statutory profit might not fully reflect the company's underlying earning capacity due to unusual item expense. The change from loss to profit is a positive turn for the firm.
復宏漢霖股票討論區
UOBKH: Healthcare – China (Overweight)
UOBKH: Healthcare – China (Overweight) - Alpha Edge Investing
$藥明生物(02269.HK)$$藥明康德(02359.HK)$$信達生物(01801.HK)$$啓明醫療-B(02500.HK)$$復宏漢霖(02696.HK)$$愛爾眼科(300015.SZ)$$邁瑞醫療(300760.SZ)$
專欄港股收評:三大指數齊跌,恒指下挫近300點,濠賭股逆勢走強
港股再度表現低迷, $恒生科技指數(800700.HK)$ 午後一度大跌2.8%,收跌2.39%報4102.02點, $恒生指數(800000.HK)$ 、 $國企指數(800100.HK)$ 分別跌1.37%和1.63%,恒指下挫近300點。南下資金全日淨流入45.32億港元,大市成交額縮量至不足千億港元。
盤面上,大型科技股全線下跌, $快手-W(01024.HK)$ 、 $小米集團-W(01810.HK)$ 跌超4%, $阿里巴巴(BABA.US)$ 、 $京東集團-SW(09618.HK)$ 、 $騰訊控股(00700.HK)$ 、 $網易-S(09999.HK)$ 、 $百度集團-SW(09888.HK)$ 皆跌超2%, $美團-W(03690.HK)$ 逆勢收紅;中信預計行業Q2銷售速度將略...
DBS: China Healthcare Sector – Pharmaceutical Packaging
$微創醫療(00853.HK)$$威高股份(01066.HK)$$石藥集團(01093.HK)$$國藥控股(01099.HK)$$華潤醫療(01515.HK)$$康臣葯業(01681.HK)$$春立醫療(01858.HK)$$環球醫療(02666.HK)$$復宏漢霖(02696.HK)$$創業慧康(300451.SZ)$$柳藥集團(603368.SH)$$百濟神州(06160.HK)$
DBS: China Biotech Sector
$百濟神州(06160.HK)$$石藥集團(01093.HK)$$復宏漢霖(02696.HK)$$微創醫療(00853.HK)$$威高股份(01066.HK)$$國藥控股(01099.HK)$$華潤醫療(01515.HK)$$康臣葯業(01681.HK)$$春立醫療(01858.HK)$$環球醫療(02666.HK)$$復宏漢霖(02696.HK)$$創業慧康(300451.SZ)$$柳藥集團(603368.SH)$$百濟神州(06160.HK)$
暫無評論